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The infiltration of Th17 cells in tissues and organs during the development of many
autoimmune diseases is considered a key step toward the establishment of chronic
inflammation. Indeed, the localized and prolonged release of IL-17 in specific tissues has
been associated with an increased severity of the inflammatory response that remains
sustained over time. The cellular and molecular mechanisms behind these effects are far
from being clear. In this study we investigated the effects of two repetitive administration
of recombinant IL-17 into the murine air pouch to simulate a scenario where IL-17 is
released over time in a pre-inflamed tissue. Consistent with our previous observations,
mice receiving a single dose of IL-17 showed a transitory influx of neutrophils into the
air pouch that peaked at 24 h and declined at 48 h. Conversely, mice receiving a double
dose of the cytokine—one at time 0 and the second after 24 h—showed amore dramatic
inflammatory response with almost 2-fold increase in the number of infiltrated leukocytes
and significant higher levels of TNF-α and IL-6 in the inflammatory fluids. Further analysis
of the exacerbated inflammatory response of double-injected IL-17 mice showed a
unique cellular and biochemical profile with inflammatory monocytes as the second main
population emigrating to the pouch and IL-16 and TREM-1 as the most upregulated
cytokines found in the inflammatory fluids. Most interestingly, mice receiving a double
injection of IL-1β did not show any change in the cellular or biochemical inflammatory
response compared to those receiving a single injection or just vehicle. Collectively
these results shed some light on the function of IL-17 as pro-inflammatory cytokine and
provide possible novel ways to target therapeutically the pathogenic effects of IL-17 in
autoimmune conditions.
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INTRODUCTION
Interleukin (IL)-17 is the founding member of an evolving
family of inflammatory cytokines whose functions remain
poorly defined (1–3). Studies aimed at characterizing the
physio/pathological functions of this cytokine both in vitro and
in vivo, including our own (4–6), have shed some light on the
unique role of this cytokine in inflammation (7). In vitro, IL-17
has been shown to induce the release of inflammatory mediators
such as IL-6, IL-8, PGE2, MCP-1, and G-CSF by wide variety of
cells, including fibroblasts (8), keratinocytes (9), epithelial (10),
endothelial cells (11), and neutrophils (12, 13).
IL-17 per se is not considered a pathogenic cytokine but rather
an amplifier of an inflammatory response. In fact, IL-17 has been
reported to synergize with TNF-α for the induction of GM-CSF
(14), or with CD40-ligand for the release of IL-6, IL-8, RANTES,
and MCP-1 from a variety of cell types (15). All these findings
are consistent with previous investigations where we and others
have shown that IL-17 does not exert an inflammatory response
when injected subcutaneously in normal non-inflamed tissue
such as the soft pad of the paw of mice (6) and elicit only a mild
inflammatory response when injected into the peritoneal cavity
FIGURE 1 | Effects of single and double injection of IL-17 in the air pouch. (A) Schematic representation of the experimental design used in this study. Male C57/Bl6
mice received two injections in the dorsal air pouch within 48 h. In the single injection protocol shown on the left, mice received a first injection of IL-1β or IL-17 (1.0 µg
in 0.5ml of 0.5% CMC) at time 0 and a second injection of vehicle (0.5ml of 0.5% CMC) after 24 h. In the double injection protocol shown on the right, mice received a
first injection of IL-1β or IL-17 (1.0 µg in 0.5ml of 0.5% CMC) at time 0 and a second injection of the same inflamogen at the same concentration after 24 h. In both
protocols mice were culled at 48 h after the first injection and then analyzed for the number of inflammatory cells migrated into the pouch. (B) Number of inflammatory
cells recovered from the air pouch of mice that have received single or double injections of CMC vehicle (Vehicle; 0.5ml) or the indicated inflamogens (1.0 µg in 0.5ml
of 0.5% CMC). Data are mean ± SEM, n = 7 animals per group of a single experiment and are representative of three independent experiments with similar results.
Statistical analysis was conducted by two-way ANOVA with Bonferroni’s multiple comparisons correction, **p < 0.01 vs. vehicle injection; ##p < 0.01 vs. IL-17
single injection; ++p < 0.01 vs. IL-1β double injection.
(6, 14). Conversely, injection of IL-17 in the pre-inflamed tissue
of the air pouch caused a significant accumulation of neutrophils
in the pouch and classical inflammatory cytokines such as IL-1β,
IL-6, TNF-α, KC, and MCP-1 in the lavage fluid (6).
The fact that IL-17 causes the recruitment of PMNs to a
tissue that is already inflamed, has been proposed to be one
of the main mechanisms by which Th17 cells sustain and
exacerbate inflammation e.g., via the recruitment of innate
immune cells that would normally be present only in the initial
phase of an inflammatory response (16–18). In this context,
emerging evidences support the view that the infiltration and
in situ differentiation of Th17 cells in inflamed tissues as
the pivotal mechanism by which these cells cause damage to
the target tissues (19–22). In line with this, seminal studies
by Williams et al. proposed that the therapeutic effects of
anti-TNF-α therapies in rheumatoid arthritis are linked to
a “displacement” of Th17 cells. More specifically, treatment
with anti-TNF-α caused a surprisingly increase in the number
of Th17 cells circulating in blood—this being the result of
a reduced infiltration of the Th17 cells in the inflamed
joints with consequent improvement of the clinical score
(23–26).
Frontiers in Immunology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 2752
Maione et al. Proinflammatory Effects of IL-17
In this study, we sought to test the hypothesis that the
presence of IL-17 at a local site of inflammation over a
sustained period of time would initiate a unique series of cellular
and biochemical events. To this aim, we tested the effects of
repetitive administration of recombinant IL-17 into the pre-
inflamed tissues of the air pouch model by injecting it at time
0 and once again after 24 h. Our results show that the repeated
administration of this cytokine at a local site of inflammation
prompts a unique inflammatory response featured by a 4-fold
increase in the number of inflammatory leukocytes emigrated in
to the pouch and a unique pattern of inflammatory mediators
including CXCL13, IL-16, and TREM-1. Most importantly,
none of these effects were observed with mice receiving double
administration of IL-1β thus confirming our hypothesis about the
unique biological role of IL-17 in inflammatory conditions.
MATERIALS AND METHODS
Reagents
Recombinant mouse IL-17A and recombinant IL-1β (from now
on abbreviated as IL-17 and IL-1β) were purchased from R&D
System (Abingdon, UK) and dissolved in carboxymethylcellulose
(CMC 0.5% w/v). Unless otherwise specified, all the other
reagents were from Sigma-Aldrich Co. (Dorset, UK).
Mice
Male C57BL/6 mice (24–28 g; Harlan, UK) were used for all
experiments. Animals were kept under standard conditions
and maintained in a 12 h/12 h light/dark cycle at 22 ± 1◦C
in accordance with United Kingdom Home Office regulations
(Guidance on the Operation of Animals, Scientific Procedures
Act 1986), the European Union directives and following ARRIVE
guidelines. All procedures were carried out to minimize the
number of animals used and their suffering. All tests were
conducted in a blinded fashion and according to the UK Animals
Scientific Procedures Act, 1986. The local biological service unit
at Queen Mary University of London approved all experimental
protocols.
Air Pouch
Dorsal air pouches were prepared by injection of 2.5ml of air
on day 0 and day 3. On day 6, mice received the following
treatments: 1- IL-17 (1.0 µg) in 0.25ml of 0.5% CMC at time 0
and vehicle at 24 h (reported as IL-17 single injection); 2- IL-17
(1.0 µg) in 0.25ml of 0.5% CMC at time 0 and at 24 h (reported
as IL-17 double injection); 3- 0.25ml of 0.5% CMC at time 0 and
IL-17 (1.0 µg) in 0.25ml of 0.5% CMC at time 24 (reported as IL-
17 secondary injection); 4- 0.25ml of 0.5% CMC at time 0 and
at 24 h (reported as vehicle). The same experimental template
was followed for IL-1β administration. In a separate set of
experiments mice received a single IL-17 (2.0 µg) administration
at time 0 or a single injection of the IL-17 (1.0 µg) 24 h post-
vehicle injection at time 0. Mice were all sacrificed after 48 h from
the first injection and air pouches washed thoroughly with 2ml
of PBS containing 50 U/ml heparin and 3mM EDTA. Lavage
fluids were centrifuged at 220 × g for 10min at 4◦C to separate
the exudates from the inflammatory cells. Inflammatory exudates
were collected and measured to evaluate the total volume and
the level of inflammatory cytokines and chemokines, as described
below. Total cell count was performed by light microscopy after
staining in Turk’s solution (crystal violet 0.01% in 3% acetic acid).
Flow Cytometry
Cells collected from the pouch cavities were first washed with
PBS and then re-suspended in FACS buffer (PBS containing 1%
FCS and 0.02% NaN2) containing CD16/CD32 FcγIIR blocking
FIGURE 2 | Levels of (A) TNF-α and (B) IL-6 present in the inflammatory fluids of mice receiving single or double injection of IL-1β or IL-17 into the air pouch. Male
C57/Bl6 mice received a single or double injection of IL-1β or IL-17 (1.0µg in 0.5ml of 0.5% CMC) as described in Materials and Methods. The inflammatory fluids
collected from the air pouch at 48 h were used to measure the levels of TNF-α and IL-6. Data are mean ± SEM, n = 7 animals per group of a single experiment and
are representative of three independent experiments with similar results. Statistical analysis was conducted by two-way ANOVA with Bonferroni’s multiple
comparisons correction, *p < 0.05 vs. vehicle injection, **p < 0.01 vs. vehicle injection; #p < 0.05 vs. IL-17 single injection; ++p < 0.01 vs. IL-1β double injection.
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antibody (clone 93; eBioscience, Wembley, UK) for 30min at
4◦C. Thereafter, cells were labeled for 30min at 4◦C with the
following conjugated antibodies (all from eBioscience, Wembley,
UK): GR-1 (1:500; clone RB6/8C5), F4/80 (1:100; clone BMT),
B220 (1:200; clone RA3-6B2), CD115 (1:200; clone AFS98), prior
to analysis by FACS calibur using CellQuest software (Becton
Dickinson, Franklin Lakes, NJ). At least 5 × 104 cells were
analyzed per sample, and determination of positive and negative
populations was performed based on the staining attained with
irrelevant IgG isotypes. Data were analyzed by FlowJo software.
Cytokines and Chemokines Protein Array
Equal volumes (1.5ml) of the inflammatory fluids obtained
were incubated with the Precoated Proteome Profiler array
membranes (R&D Systems, Abingdon, UK) according to the
manufacturer’s instructions. Densitometric analysis of the dot
plots was performed using the AIDA software from Raytest.
Cytokine ELISA
Aliquots (100 µl) of the air pouch inflammatory fluids obtained
at different time after IL-17, IL-1β or (their respective) vehicle
injection were used neat or diluted 1:1 with assay diluents
and analyzed for the levels of IL-1, IL-6, IL-16, IL-17, TNFα,
and TREM-1 levels by ELISA according to the manufacturer’s
instructions (eBioscience, UK for IL-1, IL-6, and TNF-α and
R&D system, UK for IL-16 and TREM-1).
Statistical Analysis
The results obtained were expressed as the mean ± SEM.
Statistical analysis was performed by using one-way ANOVA
followed by Dunnett’s test when comparing more than two
groups or two-way analysis of variance (ANOVA) for multiple
comparisons followed by Bonferroni’s test. In some cases, a
student T-test was used to evaluate significance against the
hypothetical zero value. Statistical analysis was performed by
FIGURE 3 | GR-1 sub-populations amongst the inflammatory cells collected from mice receiving single or double injection of IL-17 in the air pouch. Male C57/Bl6
mice received single or double injection of IL-1β or IL-17 (1.0 µg in 0.5ml of 0.5% CMC) as described in section Materials and Methods. The inflammatory cells
collected from the air pouch at 48 h were washed, stained with GR-1 and analyzed by FACS. At difference from mice receiving vehicle control that show one main
population of GR-1+ cells, mice receiving single or double injection of IL-17 show the presence of two subpopulations: GR-1high and GR-1Int. Results are from 3
independent mice chosen randomly from a single experiment and are representative of three independent experiments with n = 7 mice/treatment.
Frontiers in Immunology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 2752
Maione et al. Proinflammatory Effects of IL-17
using GraphPad Prism 5.0 software (San Diego, CA, USA). Data
were considered statistically significant when a value of P < 0.05
was achieved.
RESULTS
Double Injection of IL-17 Into the Air Pouch
Exacerbates Inflammation
The schemes in Figure 1A show the experimental procedure
we have used to compare a short (left panel) or long (right
panel) exposure to inflammatory stimuli.We knew from previous
studies (6) that a single administration of IL-17 into a 6-day
old air pouch causes a transient infiltration of leukocytes that
becomes evident at around 4–6 h, peaks at 24 h and then declines
at 48 h. To test the effects of a continuous and localized release of
IL-17 at the site of inflammation, we administered another dose
of IL-17 or the same volume of vehicle at 24 h e.g., at the time the
inflammatory response starts to fade away. Same experimental
protocol was used for IL-1β or for vehicle-treated control mice.
All mice were sacrificed 48 h after the first treatment.
Consistent with our previous findings, 48 h after a single
injection of IL-17 or IL-1β mice showed no significant difference
in the number of inflammatory leukocytes compared to vehicle-
treated ones (Figure 1B). In contrast, mice receiving double
injection of IL-17 but not IL-1β showed a marked increase
(about 10 times more) in the number inflammatory infiltrates
compared to either vehicle—or single injection of IL-17-treated
mice thus providing first evidence for a sustained accumulation
of inflammatory cells in tissues where IL-17 levels have been
artificially kept at high levels. We also carried out differential
counts to demonstrate that the main leukocyte population
present at 48 h were monocytes in comparison to neutrophils
and lymphocytes (Supplementary Figure 1). To ensure that the
effects observed were a result of repeated exposure, and not
the same as the acute response, we included mice injected with
vehicle at time 0 and then IL-17 or IL-1β at 24 h prior to
culling and analyzing at 48 h (Supplementary Figure 2). We
FIGURE 4 | Quantification and gating strategy applied to identify monocyte populations in mice receiving single or double injection of IL-17 in the air pouch. (A) Cells
obtained from vehicle, IL-17 single or double-injected air pouches were washed, stained as detailed in section Materials and Methods and analyzed by FACS. After
first establishing the gate for background fluorescence (No staining), cells that were negative for B220 (R0; B220−ve) were gated and the plotted for F4/80 and
CD115. (B) Gated cells were next divided in F4/80high-CD115+ve (R1) and F4/80low-CD115+ve (R2) positive cells as shown in the figure. Dot plots are from a single
mouse and are representative of three separate experiments with n = 7 mice. (C) Bar graphs show the total number of F4/80high-CD115+ve (gate R1) and
F4/80low-CD115+ve (gate R2) positive cells obtained from vehicle, IL-17 single or double-injected mice. Data are mean ± SEM, n = 6 animals per group of a single
experiment and are representative of three independent experiments with similar results. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s
multiple comparisons correction, **p < 0.01 vs. vehicle injection; ++p < 0.01 vs. IL-17 single injection.
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found that there was a significant recruitment of leukocytes at
48 h following a single injection of IL-17 at 24 h, however, the
level of recruitment was still significantly exacerbated in mice
which had a received double injection of IL-17 when compared
(Supplementary Figure 2).
In order to clarify whether the differing leukocyte recruitment
profiles observed were dependent upon IL-17 concentration or
repeated IL-17 exposure we administered a single injection of
2.0 µg IL-17 at time 0 in contrast to the established protocol of
1.0 µg at 0 and 24 h (Supplementary Figure 3). We found that
the critical parameter was indeed repeated exposure rather than
IL-17 concentration (Supplementary Figure 3).
The results obtained on leukocyte recruitment were reflected
in the levels of inflammatory cytokines in the air pouch fluids.
Both TNF-α and IL-6 were significantly higher in mice receiving
a double dose of IL-17 compared to mice treated with a single
dose of IL-17 or vehicle (Figures 2A,B, respectively). Once again,
we did not observe any significant difference in the levels of IL-6
and TNF-α between vehicle and double IL-1β–injected mice. We
also confirmed that IL-17 was still present in the air pouch at 48 h
after a single injection (Supplementary Figure 4).
Double Injection of IL-17 Into the Air Pouch
Induces the Recruitment of Inflammatory
Monocytes
To investigate and compare the phenotype of the inflammatory
leukocytes recruited by single or double injection of IL-17 we
stained cells with an anti-GR-1, a pan granulocyte marker and
analyzed them by flow cytometry. Interestingly, while vehicle-
injected mice showed the presence of a single GR-1int population,
mice receiving a single or double injection of IL-17 had two
populations: a GR-1int and GR-1high (Figure 3, middle and
bottom panels, respectively). Given that GR-1 expression levels
have been previously used to distinguish neutrophils (GR-1high)
from resident (GR-1+) or inflammatory (GR-1−) monocytes
(27–29), we adopted a protocol described by Ingersoll et al. (30)
to further identify these subpopulations.
For all samples, we first gated on the B220−ve population
and then plotted for F4/80 and CD115 expression (Figure 4A).
This staining identified two populations: F4/80high/CD115+ve
(gated in R1) and F4/80low/CD115+ve (gated in R2) (Figure 4B).
As the expression level of F4/80 is commonly correlated with
the degree of maturation of monocyte/macrophages (31, 32),
we labeled the R1 population as macrophages and the R2
population as monocytes. Our results show that in double-
IL-17-injected mice, the majority of the cells recovered were
CD115+ and F4/80+ with other cells with intermediate or lower
expression of both markers. These values were strengthened by
an 0.89 % of F4/80+high/CD115+ve found in the staining for the
isotype control antibody (Supplementary Figure 5). Converting
cell percentages in gated population in absolute cell number
(Figure 4B), it was evident that in mice which received a double
injection of IL-17, both R1 and R2 gated populations were
significantly (p < 0.01) higher compared to mice that had
received a single injection of IL-17 or vehicle (Figure 4C).
We next plotted R2+ve populations for GR-1 and CD115 as
the level of expression of Ly6C antigen (recognized by the anti–
Gr-1 clone RB6-8C5) would allow us to distinguish GR-1+high
inflammatory monocytes from GR-1+low patrolling monocytes.
As shown in Figure 5A, there was a clear enrichment (55.2%) of
GR-1+high inflammatory monocytes in mice receiving a double
injection of IL-17 compared to vehicle (29.9%) or single (42.7%)
IL-17-injected.
FIGURE 5 | Elevated pro-inflammatory monocyte recruitment in mice receiving double injection of IL-17. (A) F4/80low-CD115+ve positive cells (gate R2 described in
Figure 4) obtained from vehicle, IL-17 single or double-injected mice were plotted for Gr-1 and CD115. Dot plots are from a single mouse and are representative of
three separate experiments with n = 7 mice. (B) Bar graph shows the total number of GR-1high-CD115+ve positive cells obtained from vehicle, IL-17 single or
double-injected mice. Data are mean ± SEM, n = 6 animals per group. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s multiple comparisons
correction, **p < 0.01 vs. vehicle injection; ++p < 0.01 vs. IL-17 single injection.
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Conversion of percentages in absolute numbers further
highlighted these differences and showed a genuine role for IL-
17 as a cytokine that favors the recruitment of inflammatory
monocytes at the site of injury (Figure 5B).
Double Injection of IL-17 Into the Air Pouch
Increases the Release of IL-16 and TREM-1
in the Inflammatory Fluid
To gain some insights into other possible differences in the
inflammatory response caused by a single or double injection
of IL-17 we used an unbiased approach based on profiling
cytokines and chemokines present in the inflammatory fluids
using a pre-made protein array. As shown in Figure 6, the fluid
obtained from a single administration of IL-17 showed the same
profile of chemokines and cytokines present in vehicle (compare
right and left panels, respectively). These included CXCL9,
CXCL10, and CXCL13, soluble receptors such as soluble ICAM
(sICAM) and TREM-1 and cytokines such as IL-16. However,
densitometric analysis of the signals obtained from the two arrays
(Figures 6A,B,D) showed that IL-17 single injection fluid had
a specific increase in the following factors CXCL9, 10, and 13,
IL-1 and IL-16 and sICAM compared to vehicle control. When
comparing fluids from the single with the double we observed
a selective increase (∼4 time more) (Figures 6C,E) in CCL2,
IL-16, and TREM-1. To further confirm the validity of these
semi-quantitative findings and their specificity, we performed a
standard ELISA for IL-16 and TREM-1 using the fluids obtained
from multiple experiments including those with a single and
double injection of IL-1β. As shown in Figure 7, only the fluids
obtained from mice receiving a double injection of IL-17 showed
a substantial increase of both cytokines with IL-16 being 5 times
FIGURE 6 | Survey of inflammatory mediators collected from mice receiving single and double injection of IL-17 in the air pouch. Inflammatory fluids obtained from air
pouch were assayed as described in Materials and methods using a Proteome Profiler cytokine array (R&D system). The insets highlighted by the dotted lines show a
magnification of specific areas where a signal was detected. The factors shown in red are mediators that are higher in the fluids obtained from (B) single and (C)
double IL-17-injected mice compared to (A) vehicle control and single IL-17-injected mice, respectively. (D–E) Lavage fluid from a total of 7 mice per condition was
pooled for each condition and run on a single blot. The bar graph shows the densitometric analysis of the arrays showed in (A–C). Bars show mean changes ± S.E.M
of the densitometric values obtained as a delta of increase in the O.D./mm2 compared to background. Statistical analysis was conducted by Students T-Test,
*p < 0.05 and **p < 0.01 vs. (D) vehicle injection and (E) single IL-17-injected mice.
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and TREM-1 about 6 times higher than vehicle. Consistent with
the results obtained in Figure 6, there was also a doubling of the
levels of IL-16 in the fluid of mice injected with a single dose
of IL-17 mice compared to vehicle. However, these differences
did not reach statistical significance. To ensure that the effects
observed were a result of repeated exposure, and not the same as
the acute response, we includedmice injected with vehicle at time
0 and then IL-17 or Vehicle (secondary injection) at 24 h prior
to culling and analyzing of both cytokines at 48 h (Figures 8, 9).
We found that there was not a significant increase in terms of
IL-16 and TREM-1 compare to vehicle, however, their level was
still significantly decreased in mice which had a received double
injection of IL-17 when compared.
DISCUSSION
The last decade has given birth to a “firework” of cytokines that
have all been reported to play a significant role in inflammation
(33–35). Some of these cytokines have been proposed to be cell
signature e.g., to be specifically produced by a unique type of cell
to the point that the cells were named after the cytokine (36, 37).
Yet, these initial findings have been soon confuted as neither the
cytokine nor the cells were that “unique” after all. This certainly
is the case of IL-17 which was initially proposed to be specifically
produced by autoimmune pro-inflammatory Th17 cells and later
discovered to be produced at much higher level by non-Th17
cells (38–40)—to play host-protective functions against fungal
infection (41)—and to be co-produced with anti-inflammatory
cytokines such as IL-10 (42).
We have been interested in IL-17 from another perspective
and we argued that studying the biological effects of this cytokine
per se—rather than the producing cells—would help us gain
more insight in its role in chronic inflammation (4–6, 43).
In our previous studies (6) we have shown that recombinant
IL-17 was unable to initiate an inflammatory response when
injected in a tissue like the soft pad of the paw or into
the peritoneal cavity of mice. However, injection of the same
cytokine in the pre-inflamed cavity of an air pouch provided a
completely different picture e.g., a time-defined recruitment of
neutrophils and inflammatory monocytes that faded away over
48 h (6). This was consistent with existing literature proposing
IL-17 as a genuine amplifier of the immune response because
of the recruitment at the site of chronic inflammation of
classical early phase inflammatory cells like neutrophils (2, 3,
9).
This sustained recruitment of neutrophils—at the later stages
of an inflammatory response—has been proposed to be IL-17’s
main contribution to chronic inflammation (44–48). Here we
expanded these initial observations adding another dimension
to our established experimental system: time. In other words,
here we have investigated what would be the effect of a
persistent “presence” of IL-17 in a pre-inflamed tissue and,
to do so, we have administered recombinant IL-17 into the
pouch twice at time 0 and 24 h after the single injection.
Consistent with our proposed role of an “amplifier” cytokine,
double administration of IL-17 results in higher infiltration of
leukocytes compared to a single dose. We wanted to make
sure that this was not just the results of “double dose” of the
inflammatory agent injected in the pouch and we thus tested
FIGURE 7 | Levels of (A) IL-16 and (B) TREM-1 present in the inflammatory fluids of mice receiving single or double injection of IL-1β or IL-17 into the air pouch. Male
C57/Bl6 mice received single or double injection of IL-1β or IL-17 (1.0µg in 0.5ml of 0.5% CMC) as described in Materials and Methods. The inflammatory fluids
collected from the air pouch at 48 h were used to measure the levels of TNF-α and IL-6. Data are mean ± SEM, n = 7 animals per group of a single experiment and
are representative of three independent experiments with similar results. Statistical analysis was conducted by two-way ANOVA with Bonferroni’s multiple
comparisons correction, **p < 0.01 vs. vehicle injection; ##p < 0.01 vs. IL-17 single injection; ++p < 0.01 vs. IL-1β double injection.
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FIGURE 8 | Levels of IL-16 in the inflammatory fluids of mice receiving IL-17 at different time-point. (A) Schematic representation of the experimental design used in
this study. Male C57/Bl6 mice received one or two injections in the dorsal air pouch within 48 h. In the double injection protocol shown on the left (A), mice received a
first injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) at time 0 and a second injection of the cytokine after 24 h. In the secondary injection protocol (secondary
injection) shown on the right (B), mice received an injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) 24 h post-vehicle (0.5ml of 0.5% CMC) injection at time 0. In both
protocols mice were culled at 48 h after model induction and then analyzed for the level of IL-16 into the pouch (C). Data are mean ± SEM, n = 7 animals per group of
a single experiment. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s multiple comparisons correction, **p < 0.01 vs. vehicle injection;
#p < 0.05 and ##p < 0.01 vs. IL-17 single or secondary injection.
the effect of a double injection of IL-1β but the results did not
show any significant increase in the recruitment of inflammatory
cells.
We speculated if the double number of inflammatory
leukocytes we found was just the result of a continual
accumulation of neutrophils or if other cells were being
recruited by the double injection of IL-17. Analysis of
the CD115+/F4/80+ cells to identify monocyte/macrophage
(32) provided us with two populations: CD115+/F4/80high
mature macrophage and CD115+/F4/80low monocytes.. Plotting
the CD115+/F4/80low against GR-1+ showed a well-defined
population of CD115+/F4/80low/GR-1high clearly distinguishable
from the CD115+/F4/80low/GR-1low. Both populations were
more abundant in IL-17-double injected mice compared to IL-
17 single or vehicle double injected animals that appeared to be
indistinguishable (see Figure 5).
GR-1 recognizes both Ly6C and Ly6G antigens (29, 49);
therefore, it seems reasonable to define the former monocytic
lineage population as Ly6Chigh inflammatory monocytes and
the latter as Ly6Clow patrolling monocytes (50). The exact
functions of these two distinct cell populations requires further
investigation but one possible explanation may be that the
CD115+ GR-1+F4/80low monocytes are recruited to the air
pouch to contribute to inflammation development, whereas the
GR-1−F4/80high cells derive from patrolling Ly6Clow monocytes
which differentiate into macrophages in the pouch to promote
inflammation resolution presumably via apoptotic neutrophil
efferocytosis and wound healing facilitation (51–53).
Studies in the literature, have reported that Ly6Chi monocytes
express higher levels of IL-17RA than Ly6Clo monocytes which
makes them a preferential cellular responder to the inflammatory
effects of IL-17 (54). Consistent with this, studies have shown that
IL-17A−/− mice present a defective neutrophil and monocyte
recruitment in model of urinary tract infection by uropathogenic
Escherichia Coli (55). Studies on the same mice have also shown
a delayed healing by Ly6CloMHC-IIhi monocytes in models of
wound healing (56) further providing a link between IL-17 and
monocyte/macrophages.
We wanted to understand if there were other ways in which
the inflammatory response caused by the double injection of
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FIGURE 9 | Levels of TREM-1 in the inflammatory fluids of mice receiving IL-17 at different time-point. (A) Schematic representation of the experimental design used
in this study. Male C57/Bl6 mice received one or two injections in the dorsal air pouch within 48 h. In the double injection protocol shown on the left (A), mice received
a first injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) at time 0 and a second injection of the cytokine after 24 h. In the secondary injection protocol (secondary
injection) shown on the right (B), mice received an injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) 24 h post-vehicle (0.5ml of 0.5% CMC) injection at time 0. In both
protocols mice were culled at 48 h after model induction and then analyzed for the level of TREM-1 into the pouch (C). Data are mean ± SEM, n = 7 animals per
group of a single experiment. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s multiple comparisons correction, **p < 0.01 vs. vehicle
injection; ##p < 0.01 vs. IL-17 single or secondary injection.
IL-17 would differ from that of the single injection and whether,
like in the case of the monocytes, there were other soluble
inflammatory mediators that would specifically increase in this
setting. Both classical inflammatory cytokine TNF-α and IL-6
almost doubled in their levels in IL-17 double injected but not IL-
1β or vehicle double injected mice (Figure 2) but these were not
the only inflammatory mediators that were markedly increased
in the inflammatory fluids.
A number of CXC and CC chemokines as well as sICAM-1
were induced upon single administration of IL-17 in comparison
to the vehicle-treated animals (Figure 6). This is in line with
earlier published work where IL-17 was shown to upregulate
the secretion of pro-inflammatory chemokines such as CXCL2,
CXCL10, CCL20, and CCL5 (55). Surprisingly, we did not
detect any IL-8 in the air pouch which would justify the
neutrophil recruitment in our model but instead detected
the monocyte-derived chemokine CXCL10 and CCL4 and the
lymphocyte recruiting CXCL9 and CXCL13. Interestingly, when
we compared the single with the double injection of IL-17
we observed a 4-fold increase in the levels of two specific
inflammatory mediators: IL-16 and TREM-1 (Figures 7, 8).
TREM-1 is a DAP12-associated receptor expressed on
neutrophils and monocytes (57) that plays a key role in the
protecting the host against fungal allergens (58), parasites
(59) as well as in bacterial sepsis (60, 61), collagen-induced
arthritis (62), and inflammation-associated tumor development
(63). Interesting studies have also suggested that TREM-1 is
involved in neutrophil migration across the epithelium (64) and
macrophage infiltration at pathological sites (63) thus providing
a possible explanation for the amplified inflammatory response
we observed in our system.
IL-16 is classically considered as a CD4+ T cell
chemoattractant cytokine whose role in inflammation has
been demonstrated in a handful of inflammatory diseases
such as experimental autoimmune encephalomyelitis (65, 66),
rheumatoid arthritis (67), and allergy (68). A very interesting
study by Cho et al. demonstrated that fibroblast-like synoviocytes
from rheumatoid arthritis patients express higher levels of IL-16
compared to those from osteoarthritis patients (69). Most
relevant to this study, IL-17 but not with IL-15, IL-1β, and IFN-γ
were able to further increase the level of expression of IL-16
in fibroblast-like synoviocytes. The air-pouch is historically
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considered a model of “pannus formation” (70, 71) in the joint
of rheumatoid arthritis patients. It would therefore be very
tempting speculate that the lining tissue of the pouch—together
with the infiltrated immune cells—is the biological source of
IL-16.
What we think is most interesting and novel in this study is
the possibility of the existence of two classes of inflammatory
mediators: the inducers and the amplifiers. Such concept has
already been proposed in the context of NF-κB signaling where
IL-6 and TNF-α have been baptized as early inflammatory
mediators as opposed to IFN-β related genes, cyclo-oxygenase
(COX)-2 and inducible nitric oxide synthase (iNOS) (72, 73)
being the late contributors to the sustaining of the inflammatory
response. The consolidation of this hypothesis and classification
would be important from translational point of view as drugs
targeting the amplifiersmight provide a better solution for several
chronic inflammatory diseases as it would keep the response
of the host to infection intact. This indeed is one of the main
limitations of anti-TNF-α therapy that while effective in a wide
variety of autoimmune disorders, it carries the risk of an impaired
effective response to serious infections including tuberculosis
(74).
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Supplementary Figure 1 | Differential leukocyte counts after double injection of
IL-17. (A) Schematic representation of the experimental design used in this study.
Male C57/Bl6 mice received two injections of IL-17 (1.0 µg in 0.5ml of 0.5%
CMC) at time 0 and 24 in the dorsal air pouchs. (B) Differential cell count of
inflammatory cells recovered from the air pouch of mice that have received double
injection of IL-17. Data are mean ± SEM, n = 7 animals per group of a single
experiment. Statistical analysis was conducted by Students T-Test, ∗∗p < 0.01
when compared to vehicle.
Supplementary Figure 2 | Effects of secondary and double injection of IL-17 in
the air pouch. (A) Schematic representation of the experimental design used in
this study. Male C57/Bl6 mice received one or two injections in the dorsal air
pouch within 48 h. In the double injection protocol shown on the left (A), mice
received a first injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) at time 0 and a
second injection of the cytokine after 24 h. In the secondary injection protocol
(secondary injection) shown on the right (B), mice received an injection of IL-1β or
IL-17 (1.0 µg in 0.5ml of 0.5% CMC) 24 h post-vehicle (0.5ml of 0.5% CMC)
injection at time 0. In both protocols mice were culled at 48 h after model
induction and then analyzed for the number of inflammatory cells migrated into the
pouch. (C) Number of inflammatory cells recovered from the air pouch of mice
that have received a single or double injections of CMC vehicle (Vehicle; 0.5ml) or
the indicated inflamogens (1.0 µg in 0.5ml of 0.5% CMC). Data are mean ± SEM,
n = 7 animals per group of a single experiment. Statistical analysis was conducted
by one-way ANOVA with Bonferroni’s multiple comparisons correction, ∗∗p < 0.01
vs. vehicle injection; #p < 0.05 vs. IL-17 secondary injection; ++p < 0.01 vs.
IL-1β secondary injection.
Supplementary Figure 3 | Effects of single and double injection of IL-17 in the air
pouch at different time-point. Male C57/Bl6 mice received different IL-17 injections
in the dorsal air pouch within 48 h. In the double injection protocol, mice received
a first injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) at time 0 and a second
injection of the same inflamogen at the same concentration after 24 h (A). In the
single injection protocol, mice received a single IL-17 (2.0 µg in 0.5ml of 0.5%
CMC) at time 0 (B). In both protocols mice were culled at 48 h after the first
injection and then analyzed for the number of inflammatory cells migrated into the
pouch. (C) Number of inflammatory cells recovered from the air pouch of mice
that have received a single or double injections of CMC vehicle (Vehicle; 0.5ml) or
the indicated inflamogens (1.0 and 2.0 µg in 0.5ml of 0.5% CMC). Data are mean
± SEM, n = 7 animals per group of a single experiment. Statistical analysis was
conducted by two-way ANOVA with Bonferroni’s multiple comparisons correction,
∗∗p < 0.01 vs. vehicle injection; ##p < 0.01 vs. IL-17 single (2 µg) injection.
Supplementary Figure 4 | Levels of IL-17 present in the inflammatory fluids of
mice receiving a single injection of the cytokine into the air pouch. Male C57/Bl6
mice received a single injection of IL-17 (1.0 µg in 0.5ml of 0.5% CMC) as
described in section Materials and Methods (A). The inflammatory fluids collected
from the air pouch at 4, 24, and 48 h were used to measure the levels of IL-17. (B)
Bars show mean values ± S.E.M of a single experiment with n = 7 independent
mice for each time-point.
Supplementary Figure 5 | Quantification and gating strategy applied to identify
potential F4/80high-CD115+ve and F4/80low-CD115+ve positive cells with isotype
control antibody. Cells obtained from air pouches were washed, stained as
detailed in Materials and Methods and analyzed by FACS for detect
F4/80high-CD115+ve and F4/80low-CD115+ve positive cells after the staining
with isotype control antibody. Dot plots are from a single mouse and are
representative of three separate experiments with n = 7 mice.
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